As of 17 March, the FDA likelihood of approval (LoA) for Ocuphire Pharma’s Nyxol (phentolamine mesylate) in mydriasis rose by 9 points, according to GlobalData’s LoA update. The update comes after an announcement that Ocuphire’s Phase III MIRA-2 trial met its primary and multiple secondary endpoints.

While Nyxol previously had a 48% LoA, this increased to 57% after the results using GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. According to a 15 March company media release, Nyxol met its primary endpoint, with 49% of subjects treated with Nyxol returning to ≤ 0.2 mm of their baseline pupil diameter at 90 minutes, compared with just 7% on the placebo control arm (p <0.0001). It also hit multiple secondary endpoints, such as a statistically significant and more rapid return to normal pupil size across a range of dilating agents and iris colours, as well as a faster return to baseline pupil diameter at 60 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MIRA-2 evaluated Nyxol’s activity in speeding up the reversal of pharmacologically induced mydriasis in 185 patients. Participants were randomised 1:1 to receive Nyxol or a placebo one hour after receiving one of three mydriatic agents (phenylephrine, tropicamide, and Paremyd). Nyxol is a once-daily alpha-1 and alpha-2 adrenergic antagonist eye drop being developed for several indications in addition to mydriasis.

Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.